Humanetics Reports Positive Results For Phase IIA Alzheimer’s Trial

Humanetics has announced that the results of a preliminary phase IIA clinical trial suggest that a new Alzheimer’s drug NIC5-15, is safe for daily use and that cognitive performance in patients with mild to moderate disease remained stable during the six-week course of the trial.

Patients, who had an average age of 70 years, were given escalating oral doses of NIC5-15 over a 45-day period. Investigators collected preliminary evidence of treatment efficacy including cognitive and global measures and secondary outcomes including activities of daily living, behavioral disturbances, pharmacokinetic parameters and a number of Alzheimer’s disease biomarkers including Abeta peptide levels.

Ronald Zenk, president and CEO of Humanetics, said: “We are encouraged by these preliminary findings on NIC5-15. The ability to identify new treatments that can modify the progression of Alzheimer’s disease is an important milestone that Humanetics and Mount Sinai are working towards in this research. We believe that intervention with NIC5-15 can make a significant difference in people’s lives, and we are hopeful that these preliminary learnings will be supported in subsequent clinical trials.”